Anti‐cathepsin D immunotherapy triggers both innate and adaptive anti‐tumour immunity in breast cancer

Abstract

AbstractBackground and PurposeTriple‐negative breast cancer (TNBC) has poorer outcomes than other breast cancers (BC), including HER2+ BC. Cathepsin D (CathD) is a poor prognosis marker overproduced by BC cells, hypersecreted in the tumour microenvironment with tumour‐promoting activity. Here, we characterized the immunomodulatory activity of the anti‐CathD antibody F1 and its improved Fab‐aglycosylated version (F1M1) in immunocompetent mouse models of TNBC (C57BL/6 mice harbouring E0771 cell grafts) and HER2‐amplified BC (BALB/c mice harbouring TUBO cell grafts).Experimental ApproachCathD expression was evaluated by western blotting and immunofluorescence, and antibody binding to CathD by ELISA. Antibody anti‐tumour efficacy was investigated in mouse models. Immune cell recruitment and activation were assessed by immunohistochemistry, immunophenotyping, and RT‐qPCR.Key ResultsF1 and F1M1 antibodies remodelled the tumour immune landscape. Both antibodies promoted innate antitumour immunity by preventing the recruitment of immunosuppressive M2‐polarized tumour‐associated macrophages (TAMs) and by activating natural killer cells in the tumour microenvironment of both models. This translated into a reduction of T‐cell exhaustion markers in the tumour microenvironment that could be locally supported by enhanced activation of anti‐tumour antigen‐presenting cell (M1‐polarized TAMs and cDC1 cells) functions. Both antibodies inhibited tumour growth in the highly‐immunogenic E0771 model, but only marginally in the immune‐excluded TUBO model, indicating that anti‐CathD immunotherapy is more relevant for BC with a high immune cell infiltrate, as often observed in TNBC.Conclusion and implicationAnti‐CathD antibody‐based therapy triggers the anti‐tumour innate and adaptive immunity in preclinical models of BC and is a promising immunotherapy for immunogenic TNBC.